|
ACE Arthritis Medications Report Card Where does your province rank? Advanced therapies such as biologics (originator and biosimilar) and targeted small molecule medications, deliver value both medically and socially. Used in a timely and appropriate fashion, these medications are life-changing; in some cases, life-saving. However, patients with inflammatory arthritis still have unmet medication needs. The gaps in treatment are a reflection of the fact that inflammatory arthritis is a complicated disease. It is a disease driven by many different biologic processes, so no single treatment is effective for every patient. In fact, a significant number of patients do not respond well or well enough to their initial, or second or third trialed, which underlines the need for continued discovery of other therapeutic targets. Public drug plan policies at both the national, provincial, and territorial government levels are changing reimbursement access to treatment options for Canadians living with an inflammatory arthritis. The Arthritis Consumer Experts (ACE) Arthritis Medications Report Card is designed to help Canadians evaluate where their province ranks in terms of providing reimbursement for medications approved for inflammatory arthritis such as rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis and juvenile idiopathic arthritis. The ACE Arthritis Medications Report Card tracks advanced therapy disease modifying anti-rheumatic drugs (or DMARDs) used to treat the most common types of inflammatory arthritis:
|
||||||||
| 1st : Ontario (Last year: 1st) | ||||||||
| generic name (Brand Name) | rheumatoid arthritis | axial spondyloarthritis | juvenile arthritis | psoriatic arthritis | lupus | vasculitis | osteoporosis | |
| ankylosing spondylitis | non-radiographic axial spondyloarthritis (not visible on X-ray) | |||||||
| abatacept (Orencia®) | Listed—CBC | No NOC | No NOC | Listed—CBC | No Info | No NOC | No NOC | No NOC |
| adalimumab (Humira®, boDMARD) | Not Reimbursed | Not Reimbursed | No NOC | Not Reimbursed | Not Reimbursed | No NOC | No NOC | No NOC |
| adalimumab (Abrilada®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Amgevita®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Hadlima®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Hulio®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Hyrimoz®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Idacio®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Simlandi®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Yuflyma®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| anakinra (Kineret®) | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC | No NOC |
| anifrolumab (Saphnelo®) | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC |
| belimumab (Benlysta®) | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC |
| bimekizumab (Bimzelx®) | No NOC | Under Review | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| canakinumab (Ilaris®) | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC | No NOC |
| certolizumab pegol (Cimzia®) | Listed—CBC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| denosumab (Prolia®, boDMARD) | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC |
| denosumab (Jubbonti®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC |
| etanercept (Enbrel®, boDMARD) | Not Reimbursed | Not Reimbursed | No NOC | Not Reimbursed | Not Reimbursed | No NOC | No NOC | No NOC |
| etanercept (Brenzys®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| etanercept (Erelzi®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| etanercept (Rymti®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| golimumab (Simponi®) | Listed—CBC | Listed—CBC | No Info | No Info | Listed—CBC | No NOC | No NOC | No NOC |
| guselkumab (Tremfya®) | No NOC | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| infliximab (Remicade®, boDMARD) | Not Reimbursed | Not Reimbursed | No NOC | Not Reimbursed | Not Reimbursed | No NOC | No NOC | No NOC |
| infliximab (Avsola®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Inflectra®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Ixifi®, bsDMARD) | No Info | No Info | No NOC | No Info | No Info | No NOC | No NOC | No NOC |
| infliximab (Renflexis®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Remsima®, bsDMARD) | No Info | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
| ixekizumab (Taltz®) | No NOC | Under Review | No Info | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| rituximab (Rituxan®, boDMARD) | Not Reimbursed | No NOC | No NOC | Not Reimbursed | No NOC | No NOC | Not Reimbursed | No NOC |
| rituximab (Riabni®, bsDMARD) | No Info | No NOC | No NOC | No Info | No NOC | No NOC | Not Reimbursed | No NOC |
| rituximab (Riximyo®, bsDMARD) | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC |
| rituximab (Ruxience®, bsDMARD) | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC |
| rituximab (Truxima®, bsDMARD) | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC |
| romosozumab (Evenity®) | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC |
| sarilumab (Kevzara®) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
| secukinumab (Cosentyx®) | No NOC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| tocilizumab (Actemra®) | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC |
| ustekinumab (Stelara®, boDMARD) | No NOC | No NOC | No NOC | No NOC | Declined | No NOC | No NOC | No NOC |
| ustekinumab (Jamteki®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| ustekinumab (Steqeyma®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| ustekinumab (Wezlana®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
|
apremilast (Otezla®)
Auro-Apremilast, Jamp Apremilast, Sandoz Apremilast |
No NOC | No NOC | No NOC | No NOC | Declined | No NOC | No NOC | No NOC |
| baricitinib (Olumiant®) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
|
tofacitinib (Xeljanz®)
Auro-tofacitinib, Jamp tofacitinib, PMS-tofacitinib, Taro-tofacitinib |
Listed—CBC | No NOC | No NOC | No NOC | No Info | No NOC | No NOC | No NOC |
| upadacitinib (Rinvoq®) | Listed—CBC | No Info | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| 2nd : Québec (Last year: 2nd) | ||||||||
| generic name (Brand Name) | rheumatoid arthritis | axial spondyloarthritis | juvenile arthritis | psoriatic arthritis | lupus | vasculitis | osteoporosis | |
| ankylosing spondylitis | non-radiographic axial spondyloarthritis (not visible on X-ray) | |||||||
| abatacept (Orencia®) | Listed—CBC | No NOC | No NOC | Listed—CBC | Under Review | No NOC | No NOC | No NOC |
| adalimumab (Humira®, boDMARD) | Not Reimbursed | Not Reimbursed | No NOC | Not Reimbursed | Not Reimbursed | No NOC | No NOC | No NOC |
| adalimumab (Abrilada®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Amgevita®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Hadlima®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Hulio®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Hyrimoz®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Idacio®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Simlandi®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Yuflyma®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| anakinra (Kineret®) | Declined | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
| anifrolumab (Saphnelo®) | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC |
| belimumab (Benlysta®) | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC |
| bimekizumab (Bimzelx®) | No NOC | Listed—CBC | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| canakinumab (Ilaris®) | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC | No NOC |
| certolizumab pegol (Cimzia®) | Listed—CBC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| denosumab (Prolia®, boDMARD) | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC |
| denosumab (Jubbonti®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC |
| etanercept (Enbrel®, boDMARD) | Not Reimbursed | Not Reimbursed | No NOC | Not Reimbursed | Not Reimbursed | No NOC | No NOC | No NOC |
| etanercept (Brenzys®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| etanercept (Erelzi®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| etanercept (Rymti®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| golimumab (Simponi®) | Listed—CBC | Listed—CBC | Under Review | No Info | Listed—CBC | No NOC | No NOC | No NOC |
| guselkumab (Tremfya®) | No NOC | No NOC | No NOC | No NOC | Declined | No NOC | No NOC | No NOC |
| infliximab (Remicade®, boDMARD) | Not Reimbursed | Not Reimbursed | No NOC | Listed—CBC | Not Reimbursed | No NOC | No NOC | No NOC |
| infliximab (Avsola®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Inflectra®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Ixifi®, bsDMARD) | No Info | No Info | No NOC | No Info | No Info | No NOC | No NOC | No NOC |
| infliximab (Renflexis®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Remsima®, bsDMARD) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
| ixekizumab (Taltz®) | No NOC | Listed—CBC | No Info | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| rituximab (Rituxan®, boDMARD) | Not Reimbursed | No NOC | No NOC | No NOC | No NOC | No NOC | Not Reimbursed | No NOC |
| rituximab (Riabni®, bsDMARD) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | Under Review | No NOC |
| rituximab (Riximyo®, bsDMARD) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC |
| rituximab (Ruxience®, bsDMARD) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC |
| rituximab (Truxima®, bsDMARD) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC |
| romosozumab (Evenity®) | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC |
| sarilumab (Kevzara®) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
| secukinumab (Cosentyx®) | No NOC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| tocilizumab (Actemra®) | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC |
| ustekinumab (Stelara®, boDMARD) | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| ustekinumab (Jamteki®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| ustekinumab (Steqeyma®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| ustekinumab (Wezlana®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
|
apremilast (Otezla®)
Auro-Apremilast, Jamp Apremilast, Sandoz Apremilast |
No NOC | No NOC | No NOC | No NOC | Declined | No NOC | No NOC | No NOC |
| baricitinib (Olumiant®) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
|
tofacitinib (Xeljanz®)
Auro-tofacitinib, Jamp tofacitinib, PMS-tofacitinib, Taro-tofacitinib |
Listed—CBC | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| upadacitinib (Rinvoq®) | Listed—CBC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| 3rd : New Brunswick (Last year: 6th) | ||||||||
| generic name (Brand Name) | rheumatoid arthritis | axial spondyloarthritis | juvenile arthritis | psoriatic arthritis | lupus | vasculitis | osteoporosis | |
| ankylosing spondylitis | non-radiographic axial spondyloarthritis (not visible on X-ray) | |||||||
| abatacept (Orencia®) | Listed—CBC | No NOC | No NOC | Listed—CBC | Under Review | No NOC | No NOC | No NOC |
| adalimumab (Humira®, boDMARD) | Not Reimbursed | Not Reimbursed | No NOC | Not Reimbursed | Not Reimbursed | No NOC | No NOC | No NOC |
| adalimumab (Abrilada®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Amgevita®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Hadlima®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Hulio®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Hyrimoz®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Idacio®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Simlandi®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Yuflyma®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| anakinra (Kineret®) | Under Review | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
| anifrolumab (Saphnelo®) | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC |
| belimumab (Benlysta®) | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC |
| bimekizumab (Bimzelx®) | No NOC | Under Review | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| canakinumab (Ilaris®) | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC | No NOC |
| certolizumab pegol (Cimzia®) | Listed—CBC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| denosumab (Prolia®, boDMARD) | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC |
| denosumab (Jubbonti®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | Under Review |
| etanercept (Enbrel®, boDMARD) | Not Reimbursed | Not Reimbursed | No NOC | Not Reimbursed | Not Reimbursed | No NOC | No NOC | No NOC |
| etanercept (Brenzys®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| etanercept (Erelzi®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| etanercept (Rymti®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| golimumab (Simponi®) | Listed—CBC | Listed—CBC | Under Review | No Info | Listed—CBC | No NOC | No NOC | No NOC |
| guselkumab (Tremfya®) | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Remicade®, boDMARD) | Not Reimbursed | Not Reimbursed | No NOC | No NOC | Not Reimbursed | No NOC | No NOC | No NOC |
| infliximab (Avsola®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | No Info | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Inflectra®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | No Info | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Ixifi®, bsDMARD) | No Info | No Info | No NOC | No Info | No Info | No NOC | No NOC | No NOC |
| infliximab (Renflexis®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | No Info | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Remsima®, bsDMARD) | Under Review | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
| ixekizumab (Taltz®) | No NOC | Declined | No Info | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| rituximab (Rituxan®, boDMARD) | Not Reimbursed | No NOC | No NOC | No NOC | No NOC | No NOC | Not Reimbursed | No NOC |
| rituximab (Riabni®, bsDMARD) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC |
| rituximab (Riximyo®, bsDMARD) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC |
| rituximab (Ruxience®, bsDMARD) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC |
| rituximab (Truxima®, bsDMARD) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC |
| romosozumab (Evenity®) | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC |
| sarilumab (Kevzara®) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
| secukinumab (Cosentyx®) | No NOC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| tocilizumab (Actemra®) | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC |
| ustekinumab (Stelara®, boDMARD) | No NOC | No NOC | No NOC | No NOC | Declined | No NOC | No NOC | No NOC |
| ustekinumab (Jamteki®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| ustekinumab (Steqeyma®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| ustekinumab (Wezlana®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
|
apremilast (Otezla®)
Auro-Apremilast, Jamp Apremilast, Sandoz Apremilast |
No NOC | No NOC | No NOC | No NOC | Declined | No NOC | No NOC | No NOC |
| baricitinib (Olumiant®) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
|
tofacitinib (Xeljanz®)
Auro-tofacitinib, Jamp tofacitinib, PMS-tofacitinib, Taro-tofacitinib |
Listed—CBC | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| upadacitinib (Rinvoq®) | Listed—CBC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| 4th : Manitoba (Last year: 6th) | ||||||||
| generic name (Brand Name) | rheumatoid arthritis | axial spondyloarthritis | juvenile arthritis | psoriatic arthritis | lupus | vasculitis | osteoporosis | |
| ankylosing spondylitis | non-radiographic axial spondyloarthritis (not visible on X-ray) | |||||||
| abatacept (Orencia®) | Listed—CBC | No NOC | No NOC | No Info | Under Review | No NOC | No NOC | No NOC |
| adalimumab (Humira®, boDMARD) | Not Reimbursed | Not Reimbursed | No NOC | Not Reimbursed | Not Reimbursed | No NOC | No NOC | No NOC |
| adalimumab (Abrilada®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Amgevita®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Hadlima®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Hulio®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Hyrimoz®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Idacio®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Simlandi®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Yuflyma®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| anakinra (Kineret®) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
| anifrolumab (Saphnelo®) | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC |
| belimumab (Benlysta®) | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC |
| bimekizumab (Bimzelx®) | No NOC | Under Review | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| canakinumab (Ilaris®) | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC | No NOC |
| certolizumab pegol (Cimzia®) | Listed—CBC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| denosumab (Prolia®, boDMARD) | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC |
| denosumab (Jubbonti®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC |
| etanercept (Enbrel®, boDMARD) | Not Reimbursed | Not Reimbursed | No NOC | Not Reimbursed | Not Reimbursed | No NOC | No NOC | No NOC |
| etanercept (Brenzys®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| etanercept (Erelzi®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| etanercept (Rymti®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| golimumab (Simponi®) | Listed—CBC | Listed—CBC | No Info | No Info | Listed—CBC | No NOC | No NOC | No NOC |
| guselkumab (Tremfya®) | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Remicade®, boDMARD) | Not Reimbursed | Not Reimbursed | No NOC | No Info | Not Reimbursed | No NOC | No NOC | No NOC |
| infliximab (Avsola®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | No Info | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Inflectra®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | No Info | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Ixifi®, bsDMARD) | No Info | No Info | No NOC | No Info | No Info | No NOC | No NOC | No NOC |
| infliximab (Renflexis®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | No Info | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Remsima®, bsDMARD) | No Info | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
| ixekizumab (Taltz®) | No NOC | Under Review | No Info | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| rituximab (Rituxan®, boDMARD) | Not Reimbursed | No NOC | No NOC | No NOC | No NOC | No NOC | Not Reimbursed | No NOC |
| rituximab (Riabni®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
| rituximab (Riximyo®, bsDMARD) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC |
| rituximab (Ruxience®, bsDMARD) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC |
| rituximab (Truxima®, bsDMARD) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC |
| romosozumab (Evenity®) | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC |
| sarilumab (Kevzara®) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
| secukinumab (Cosentyx®) | No NOC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| tocilizumab (Actemra®) | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC |
| ustekinumab (Stelara®, boDMARD) | No NOC | No NOC | No NOC | No NOC | No Info | No NOC | No NOC | No NOC |
| ustekinumab (Jamteki®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| ustekinumab (Steqeyma®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| ustekinumab (Wezlana®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
|
apremilast (Otezla®)
Auro-Apremilast, Jamp Apremilast, Sandoz Apremilast |
No NOC | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| baricitinib (Olumiant®) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
|
tofacitinib (Xeljanz®)
Auro-tofacitinib, Jamp tofacitinib, PMS-tofacitinib, Taro-tofacitinib |
Listed—CBC | No NOC | No NOC | No NOC | No Info | No NOC | No NOC | No NOC |
| upadacitinib (Rinvoq®) | Listed—CBC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| 4th : Nova Scotia (Last year: 6th) | ||||||||
| generic name (Brand Name) | rheumatoid arthritis | axial spondyloarthritis | juvenile arthritis | psoriatic arthritis | lupus | vasculitis | osteoporosis | |
| ankylosing spondylitis | non-radiographic axial spondyloarthritis (not visible on X-ray) | |||||||
| abatacept (Orencia®) | Listed—CBC | No NOC | No NOC | Listed—CBC | Under Review | No NOC | No NOC | No NOC |
| adalimumab (Humira®, boDMARD) | Not Reimbursed | Not Reimbursed | No NOC | Not Reimbursed | Not Reimbursed | No NOC | No NOC | No NOC |
| adalimumab (Abrilada®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Amgevita®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Hadlima®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Hulio®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Hyrimoz®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Idacio®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Simlandi®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Yuflyma®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| anakinra (Kineret®) | Under Review | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
| anifrolumab (Saphnelo®) | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC |
| belimumab (Benlysta®) | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC |
| bimekizumab (Bimzelx®) | No NOC | Under Review | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| canakinumab (Ilaris®) | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC | No NOC |
| certolizumab pegol (Cimzia®) | Listed—CBC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| denosumab (Prolia®, boDMARD) | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | Not Reimbursed |
| denosumab (Jubbonti®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | Not Reimbursed |
| etanercept (Enbrel®, boDMARD) | Not Reimbursed | Not Reimbursed | No NOC | Not Reimbursed | Not Reimbursed | No NOC | No NOC | No NOC |
| etanercept (Brenzys®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| etanercept (Erelzi®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| etanercept (Rymti®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| golimumab (Simponi®) | Listed—CBC | Listed—CBC | Under Review | No Info | Listed—CBC | No NOC | No NOC | No NOC |
| guselkumab (Tremfya®) | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Remicade®, boDMARD) | Not Reimbursed | Not Reimbursed | No NOC | No Info | Not Reimbursed | No NOC | No NOC | No NOC |
| infliximab (Avsola®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | No Info | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Inflectra®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | No Info | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Ixifi®, bsDMARD) | No Info | No Info | No NOC | No Info | No Info | No NOC | No NOC | No NOC |
| infliximab (Renflexis®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | No Info | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Remsima®, bsDMARD) | Under Review | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
| ixekizumab (Taltz®) | No NOC | Under Review | No Info | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| rituximab (Rituxan®, boDMARD) | Not Reimbursed | No NOC | No NOC | No NOC | No NOC | No NOC | Not Reimbursed | No NOC |
| rituximab (Riabni®, bsDMARD) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC |
| rituximab (Riximyo®, bsDMARD) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC |
| rituximab (Ruxience®, bsDMARD) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC |
| rituximab (Truxima®, bsDMARD) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC |
| romosozumab (Evenity®) | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC |
| sarilumab (Kevzara®) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
| secukinumab (Cosentyx®) | No NOC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| tocilizumab (Actemra®) | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC |
| ustekinumab (Stelara®, boDMARD) | No NOC | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| ustekinumab (Jamteki®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| ustekinumab (Steqeyma®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| ustekinumab (Wezlana®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
|
apremilast (Otezla®)
Auro-Apremilast, Jamp Apremilast, Sandoz Apremilast |
No NOC | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| baricitinib (Olumiant®) | Under Review | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
|
tofacitinib (Xeljanz®)
Auro-tofacitinib, Jamp tofacitinib, PMS-tofacitinib, Taro-tofacitinib |
Listed—CBC | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| upadacitinib (Rinvoq®) | Listed—CBC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| 6th : Saskatchewan (Last year: 5th) | ||||||||
| generic name (Brand Name) | rheumatoid arthritis | axial spondyloarthritis | juvenile arthritis | psoriatic arthritis | lupus | vasculitis | osteoporosis | |
| ankylosing spondylitis | non-radiographic axial spondyloarthritis (not visible on X-ray) | |||||||
| abatacept (Orencia®) | Listed—CBC | No NOC | No NOC | Listed—CBC | No Info | No NOC | No NOC | No NOC |
| adalimumab (Humira®, boDMARD) | Not Reimbursed | Not Reimbursed | No NOC | Not Reimbursed | Not Reimbursed | No NOC | No NOC | No NOC |
| adalimumab (Abrilada®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Amgevita®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Hadlima®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Hulio®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Hyrimoz®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Idacio®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Simlandi®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Yuflyma®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| anakinra (Kineret®) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
| anifrolumab (Saphnelo®) | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC |
| belimumab (Benlysta®) | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC |
| bimekizumab (Bimzelx®) | No NOC | Under Review | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| canakinumab (Ilaris®) | No NOC | No NOC | No NOC | Declined | No NOC | No NOC | No NOC | No NOC |
| certolizumab pegol (Cimzia®) | Listed—CBC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| denosumab (Prolia®, boDMARD) | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC |
| denosumab (Jubbonti®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | Under Review |
| etanercept (Enbrel®, boDMARD) | Not Reimbursed | Not Reimbursed | No NOC | Not Reimbursed | Not Reimbursed | No NOC | No NOC | No NOC |
| etanercept (Brenzys®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| etanercept (Erelzi®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| etanercept (Rymti®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| golimumab (Simponi®) | Listed—CBC | Listed—CBC | No Info | No Info | Listed—CBC | No NOC | No NOC | No NOC |
| guselkumab (Tremfya®) | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Remicade®, boDMARD) | Not Reimbursed | Not Reimbursed | No NOC | No Info | Not Reimbursed | No NOC | No NOC | No NOC |
| infliximab (Avsola®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | No Info | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Inflectra®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | No Info | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Ixifi®, bsDMARD) | No Info | No Info | No NOC | No Info | No Info | No NOC | No NOC | No NOC |
| infliximab (Renflexis®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | No Info | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Remsima®, bsDMARD) | Declined | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
| ixekizumab (Taltz®) | No NOC | No Info | No Info | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| rituximab (Rituxan®, boDMARD) | Not Reimbursed | No NOC | No NOC | No NOC | No NOC | No NOC | Not Reimbursed | No NOC |
| rituximab (Riabni®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
| rituximab (Riximyo®, bsDMARD) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC |
| rituximab (Ruxience®, bsDMARD) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC |
| rituximab (Truxima®, bsDMARD) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC |
| romosozumab (Evenity®) | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC |
| sarilumab (Kevzara®) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
| secukinumab (Cosentyx®) | No NOC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| tocilizumab (Actemra®) | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC |
| ustekinumab (Stelara®, boDMARD) | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| ustekinumab (Jamteki®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | No Info | No NOC | No NOC | No NOC |
| ustekinumab (Steqeyma®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | No Info | No NOC | No NOC | No NOC |
| ustekinumab (Wezlana®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | No Info | No NOC | No NOC | No NOC |
|
apremilast (Otezla®)
Auro-Apremilast, Jamp Apremilast, Sandoz Apremilast |
No NOC | No NOC | No NOC | No NOC | Declined | No NOC | No NOC | No NOC |
| baricitinib (Olumiant®) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
|
tofacitinib (Xeljanz®)
Auro-tofacitinib, Jamp tofacitinib, PMS-tofacitinib, Taro-tofacitinib |
Listed—CBC | No NOC | No NOC | No NOC | No Info | No NOC | No NOC | No NOC |
| upadacitinib (Rinvoq®) | Listed—CBC | No Info | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| 7th : Alberta (Last year :3rd) | ||||||||
| generic name (Brand Name) | rheumatoid arthritis | axial spondyloarthritis | juvenile arthritis | psoriatic arthritis | lupus | vasculitis | osteoporosis | |
| ankylosing spondylitis | non-radiographic axial spondyloarthritis (not visible on X-ray) | |||||||
| abatacept (Orencia®) | Listed—CBC | No NOC | No NOC | Listed—CBC | No Info | No NOC | No NOC | No NOC |
| adalimumab (Humira®, boDMARD) | Not Reimbursed | Not Reimbursed | No NOC | Not Reimbursed | Not Reimbursed | No NOC | No NOC | No NOC |
| adalimumab (Abrilada®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Amgevita®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Hadlima®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Hulio®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Hyrimoz®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Idacio®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Simlandi®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Yuflyma®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| anakinra (Kineret®) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
| anifrolumab (Saphnelo®) | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC |
| belimumab (Benlysta®) | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC |
| bimekizumab (Bimzelx®) | No NOC | Under Review | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| canakinumab (Ilaris®) | No NOC | No NOC | No NOC | Declined | No NOC | No NOC | No NOC | No NOC |
| certolizumab pegol (Cimzia®) | Listed—CBC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| denosumab (Prolia®, boDMARD) | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC |
| denosumab (Jubbonti®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | Under Review |
| etanercept (Enbrel®, boDMARD) | Not Reimbursed | Not Reimbursed | No NOC | Not Reimbursed | Not Reimbursed | No NOC | No NOC | No NOC |
| etanercept (Brenzys®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| etanercept (Erelzi®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| etanercept (Rymti®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| golimumab (Simponi®) | Listed—CBC | Listed—CBC | No Info | No Info | Listed—CBC | No NOC | No NOC | No NOC |
| guselkumab (Tremfya®) | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Remicade®, boDMARD) | Not Reimbursed | Not Reimbursed | No NOC | No NOC | Not Reimbursed | No NOC | No NOC | No NOC |
| infliximab (Avsola®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Inflectra®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Ixifi®, bsDMARD) | No Info | No Info | No NOC | No Info | No Info | No NOC | No NOC | No NOC |
| infliximab (Renflexis®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Remsima®, bsDMARD) | No Info | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
| ixekizumab (Taltz®) | No NOC | Under Review | No Info | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| rituximab (Rituxan®, boDMARD) | Not Reimbursed | No NOC | No NOC | No NOC | No NOC | No NOC | Not Reimbursed | No NOC |
| rituximab (Riabni®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
| rituximab (Riximyo®, bsDMARD) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC |
| rituximab (Ruxience®, bsDMARD) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC |
| rituximab (Truxima®, bsDMARD) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC |
| romosozumab (Evenity®) | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No Info |
| sarilumab (Kevzara®) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
| secukinumab (Cosentyx®) | No NOC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| tocilizumab (Actemra®) | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC |
| ustekinumab (Stelara®, boDMARD) | No NOC | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| ustekinumab (Jamteki®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| ustekinumab (Steqeyma®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| ustekinumab (Wezlana®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
|
apremilast (Otezla®)
Auro-Apremilast, Jamp Apremilast, Sandoz Apremilast |
No NOC | No NOC | No NOC | No NOC | Declined | No NOC | No NOC | No NOC |
| baricitinib (Olumiant®) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
|
tofacitinib (Xeljanz®)
Auro-tofacitinib, Jamp tofacitinib, PMS-tofacitinib, Taro-tofacitinib |
Listed—CBC | No NOC | No NOC | No NOC | No Info | No NOC | No NOC | No NOC |
| upadacitinib (Rinvoq®) | Listed—CBC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| 8th : NIHB* (Last year: 11th) | ||||||||
| generic name (Brand Name) | rheumatoid arthritis | axial spondyloarthritis | juvenile arthritis | psoriatic arthritis | lupus | vasculitis | osteoporosis | |
| ankylosing spondylitis | non-radiographic axial spondyloarthritis (not visible on X-ray) | |||||||
| abatacept (Orencia®) | Listed—CBC | No NOC | No NOC | Listed—CBC | Under Review | No NOC | No NOC | No NOC |
| adalimumab (Humira®, boDMARD) | Not Reimbursed | Not Reimbursed | No NOC | Not Reimbursed | Not Reimbursed | No NOC | No NOC | No NOC |
| adalimumab (Abrilada®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Amgevita®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Hadlima®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Hulio®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Hyrimoz®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Idacio®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Simlandi®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Yuflyma®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| anakinra (Kineret®) | Declined | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
| anifrolumab (Saphnelo®) | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC |
| belimumab (Benlysta®) | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC |
| bimekizumab (Bimzelx®) | No NOC | Under Review | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| canakinumab (Ilaris®) | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC | No NOC |
| certolizumab pegol (Cimzia®) | Listed—CBC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| denosumab (Prolia®, boDMARD) | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC |
| denosumab (Jubbonti®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | Under Review |
| etanercept (Enbrel®, boDMARD) | Not Reimbursed | Not Reimbursed | No NOC | Not Reimbursed | Not Reimbursed | No NOC | No NOC | No NOC |
| etanercept (Brenzys®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| etanercept (Erelzi®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| etanercept (Rymti®, bsDMARD) | No Info | No Info | No NOC | No Info | No Info | No NOC | No NOC | No NOC |
| golimumab (Simponi®) | Listed—CBC | Listed—CBC | Under Review | No Info | Listed—CBC | No NOC | No NOC | No NOC |
| guselkumab (Tremfya®) | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Remicade®, boDMARD) | Not Reimbursed | Declined | No NOC | No NOC | Declined | No NOC | No NOC | No NOC |
| infliximab (Avsola®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Inflectra®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Ixifi®, bsDMARD) | No Info | No Info | No NOC | No Info | No Info | No NOC | No NOC | No NOC |
| infliximab (Renflexis®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Remsima®, bsDMARD) | Under Review | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
| ixekizumab (Taltz®) | No NOC | No NOC | No Info | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| rituximab (Rituxan®, boDMARD) | Not Reimbursed | No NOC | No NOC | No NOC | No NOC | No NOC | Not Reimbursed | No NOC |
| rituximab (Riabni®, bsDMARD) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC |
| rituximab (Riximyo®, bsDMARD) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC |
| rituximab (Ruxience®, bsDMARD) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC |
| rituximab (Truxima®, bsDMARD) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC |
| romosozumab (Evenity®) | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC |
| sarilumab (Kevzara®) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
| secukinumab (Cosentyx®) | No NOC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| tocilizumab (Actemra®) | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC |
| ustekinumab (Stelara®, boDMARD) | No NOC | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| ustekinumab (Jamteki®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| ustekinumab (Steqeyma®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| ustekinumab (Wezlana®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
|
apremilast (Otezla®)
Auro-Apremilast, Jamp Apremilast, Sandoz Apremilast |
No NOC | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| baricitinib (Olumiant®) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
|
tofacitinib (Xeljanz®)
Auro-tofacitinib, Jamp tofacitinib, PMS-tofacitinib, Taro-tofacitinib |
Listed—CBC | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| upadacitinib (Rinvoq®) | Listed—CBC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| 9th : Prince Edward Island (Last year: 10th) | ||||||||
| generic name (Brand Name) | rheumatoid arthritis | axial spondyloarthritis | juvenile arthritis | psoriatic arthritis | lupus | vasculitis | osteoporosis | |
| ankylosing spondylitis | non-radiographic axial spondyloarthritis (not visible on X-ray) | |||||||
| abatacept (Orencia®) | Listed—CBC | No NOC | No NOC | Listed—CBC | Under Review | No NOC | No NOC | No NOC |
| adalimumab (Humira®, boDMARD) | Not Reimbursed | Not Reimbursed | No NOC | Not Reimbursed | Not Reimbursed | No NOC | No NOC | No NOC |
| adalimumab (Abrilada®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Amgevita®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Hadlima®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Hulio®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Hyrimoz®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Idacio®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Simlandi®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Yuflyma®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| anakinra (Kineret®) | Under Review | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
| anifrolumab (Saphnelo®) | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC |
| belimumab (Benlysta®) | No NOC | No NOC | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC |
| bimekizumab (Bimzelx®) | No NOC | Under Review | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| canakinumab (Ilaris®) | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC | No NOC |
| certolizumab pegol (Cimzia®) | Listed—CBC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| denosumab (Prolia®, boDMARD) | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC |
| denosumab (Jubbonti®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | Under Review |
| etanercept (Enbrel®, boDMARD) | Not Reimbursed | Not Reimbursed | No NOC | Not Reimbursed | Not Reimbursed | No NOC | No NOC | No NOC |
| etanercept (Brenzys®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Under Review | Listed—CBC | No NOC | No NOC | No NOC |
| etanercept (Erelzi®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| etanercept (Rymti®, bsDMARD) | No Info | No Info | No NOC | No Info | No Info | No NOC | No NOC | No NOC |
| golimumab (Simponi®) | Listed—CBC | Listed—CBC | Under Review | No Info | Listed—CBC | No NOC | No NOC | No NOC |
| guselkumab (Tremfya®) | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Remicade®, boDMARD) | Not Reimbursed | Not Reimbursed | No NOC | No NOC | Not Reimbursed | No NOC | No NOC | No NOC |
| infliximab (Avsola®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | No Info | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Inflectra®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | No Info | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Ixifi®, bsDMARD) | No Info | No Info | No NOC | No Info | No Info | No NOC | No NOC | No NOC |
| infliximab (Renflexis®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | No Info | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Remsima®, bsDMARD) | Under Review | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
| ixekizumab (Taltz®) | No NOC | Under Review | No Info | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| rituximab (Rituxan®, boDMARD) | Not Reimbursed | No NOC | No NOC | No NOC | No NOC | No NOC | Not Reimbursed | No NOC |
| rituximab (Riabni®, bsDMARD) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC |
| rituximab (Riximyo®, bsDMARD) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC |
| rituximab (Ruxience®, bsDMARD) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC |
| rituximab (Truxima®, bsDMARD) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC |
| romosozumab (Evenity®) | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | Under Review |
| sarilumab (Kevzara®) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
| secukinumab (Cosentyx®) | No NOC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| tocilizumab (Actemra®) | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC |
| ustekinumab (Stelara®, boDMARD) | No NOC | No NOC | No NOC | No NOC | Not Reimbursed | No NOC | No NOC | No NOC |
| ustekinumab (Jamteki®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| ustekinumab (Steqeyma®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| ustekinumab (Wezlana®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
|
apremilast (Otezla®)
Auro-Apremilast, Jamp Apremilast, Sandoz Apremilast |
No NOC | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| baricitinib (Olumiant®) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
|
tofacitinib (Xeljanz®)
Auro-tofacitinib, Jamp tofacitinib, PMS-tofacitinib, Taro-tofacitinib |
Listed—CBC | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| upadacitinib (Rinvoq®) | Listed—CBC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| 10th : British Columbia (Last year: 3rd) | ||||||||
| generic name (Brand Name) | rheumatoid arthritis | axial spondyloarthritis | juvenile arthritis | psoriatic arthritis | lupus | vasculitis | osteoporosis | |
| ankylosing spondylitis | non-radiographic axial spondyloarthritis (not visible on X-ray) | |||||||
| abatacept (Orencia®) | Listed—CBC | No NOC | No NOC | Listed—CBC | No Info | No NOC | No NOC | No NOC |
| adalimumab (Humira®, boDMARD) | Not Reimbursed | Not Reimbursed | No NOC | Not Reimbursed | Not Reimbursed | No NOC | No NOC | No NOC |
| adalimumab (Abrilada®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Amgevita®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Hadlima®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Hulio®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Hyrimoz®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Idacio®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Simlandi®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Yuflyma®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| anakinra (Kineret®) | Declined | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
| anifrolumab (Saphnelo®) | No NOC | No NOC | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC |
| belimumab (Benlysta®) | No NOC | No NOC | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC |
| bimekizumab (Bimzelx®) | No NOC | Under Review | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| canakinumab (Ilaris®) | No NOC | No NOC | No NOC | Declined | No NOC | No NOC | No NOC | No NOC |
| certolizumab pegol (Cimzia®) | Listed—CBC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| denosumab (Prolia®, boDMARD) | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | Not Reimbursed |
| denosumab (Jubbonti®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC |
| etanercept (Enbrel®, boDMARD) | Not Reimbursed | Not Reimbursed | No NOC | Not Reimbursed | Not Reimbursed | No NOC | No NOC | No NOC |
| etanercept (Brenzys®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| etanercept (Erelzi®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| etanercept (Rymti®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| golimumab (Simponi®) | Listed—CBC | Listed—CBC | Under Review | No Info | Listed—CBC | No NOC | No NOC | No NOC |
| guselkumab (Tremfya®) | No NOC | No NOC | No NOC | No NOC | Declined | No NOC | No NOC | No NOC |
| infliximab (Remicade®, boDMARD) | Not Reimbursed | Not Reimbursed | No NOC | Not Reimbursed | Not Reimbursed | No NOC | No NOC | No NOC |
| infliximab (Avsola®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | No Info | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Inflectra®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | No Info | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Ixifi®, bsDMARD) | No Info | No Info | No NOC | No Info | No Info | No NOC | No NOC | No NOC |
| infliximab (Renflexis®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | No Info | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Remsima®, bsDMARD) | Declined | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
| ixekizumab (Taltz®) | No NOC | Declined | No Info | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| rituximab (Rituxan®, boDMARD) | Not Reimbursed | No NOC | No NOC | No NOC | No NOC | No NOC | Not Reimbursed | No NOC |
| rituximab (Riabni®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
| rituximab (Riximyo®, bsDMARD) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC |
| rituximab (Ruxience®, bsDMARD) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC |
| rituximab (Truxima®, bsDMARD) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC |
| romosozumab (Evenity®) | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC |
| sarilumab (Kevzara®) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
| secukinumab (Cosentyx®) | No NOC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| tocilizumab (Actemra®) | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC |
| ustekinumab (Stelara®, boDMARD) | No NOC | No NOC | No NOC | No NOC | Not Reimbursed | No NOC | No NOC | No NOC |
| ustekinumab (Jamteki®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| ustekinumab (Steqeyma®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| ustekinumab (Wezlana®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
|
apremilast (Otezla®)
Auro-Apremilast, Jamp Apremilast, Sandoz Apremilast |
No NOC | No NOC | No NOC | No NOC | Declined | No NOC | No NOC | No NOC |
| baricitinib (Olumiant®) | Declined | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
|
tofacitinib (Xeljanz®)
Auro-tofacitinib, Jamp tofacitinib, PMS-tofacitinib, Taro-tofacitinib |
Listed—CBC | No NOC | No NOC | No NOC | No Info | No NOC | No NOC | No NOC |
| upadacitinib (Rinvoq®) | Declined | Under Review | No NOC | No NOC | Declined | No NOC | No NOC | No NOC |
| 11th : Newfoundland and Labrador (Last year: 9th) | ||||||||
| generic name (Brand Name) | rheumatoid arthritis | axial spondyloarthritis | juvenile arthritis | psoriatic arthritis | lupus | vasculitis | osteoporosis | |
| ankylosing spondylitis | non-radiographic axial spondyloarthritis (not visible on X-ray) | |||||||
| abatacept (Orencia®) | Listed—CBC | No NOC | No NOC | Listed—CBC | Under Review | No NOC | No NOC | No NOC |
| adalimumab (Humira®, boDMARD) | Not Reimbursed | Not Reimbursed | No NOC | Not Reimbursed | Not Reimbursed | No NOC | No NOC | No NOC |
| adalimumab (Abrilada®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Amgevita®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Hadlima®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Hulio®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Hyrimoz®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Idacio®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Simlandi®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Yuflyma®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| anakinra (Kineret®) | Under Review | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
| anifrolumab (Saphnelo®) | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC |
| belimumab (Benlysta®) | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC |
| bimekizumab (Bimzelx®) | No NOC | Under Review | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| canakinumab (Ilaris®) | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC | No NOC |
| certolizumab pegol (Cimzia®) | Listed—CBC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| denosumab (Prolia®, boDMARD) | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | Not Reimbursed |
| denosumab (Jubbonti®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC |
| etanercept (Enbrel®, boDMARD) | Not Reimbursed | Not Reimbursed | No NOC | Not Reimbursed | Not Reimbursed | No NOC | No NOC | No NOC |
| etanercept (Brenzys®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Under Review | Under Review | No NOC | No NOC | No NOC |
| etanercept (Erelzi®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| etanercept (Rymti®, bsDMARD) | No Info | No Info | No NOC | No Info | No Info | No NOC | No NOC | No NOC |
| golimumab (Simponi®) | Listed—CBC | Listed—CBC | Under Review | No Info | Listed—CBC | No NOC | No NOC | No NOC |
| guselkumab (Tremfya®) | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Remicade®, boDMARD) | Not Reimbursed | Not Reimbursed | No NOC | No Info | Not Reimbursed | No NOC | No NOC | No NOC |
| infliximab (Avsola®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | No Info | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Inflectra®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | No Info | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Ixifi®, bsDMARD) | No Info | No Info | No NOC | No Info | No Info | No NOC | No NOC | No NOC |
| infliximab (Renflexis®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | No Info | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Remsima®, bsDMARD) | Under Review | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
| ixekizumab (Taltz®) | No NOC | Under Review | No Info | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| rituximab (Rituxan®, boDMARD) | Not Reimbursed | No NOC | No NOC | No NOC | No NOC | No NOC | Not Reimbursed | No NOC |
| rituximab (Riabni®, bsDMARD) | Under Review | No NOC | No NOC | No NOC | No NOC | No NOC | Under Review | No NOC |
| rituximab (Riximyo®, bsDMARD) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC |
| rituximab (Ruxience®, bsDMARD) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC |
| rituximab (Truxima®, bsDMARD) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC |
| romosozumab (Evenity®) | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC |
| sarilumab (Kevzara®) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
| secukinumab (Cosentyx®) | No NOC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| tocilizumab (Actemra®) | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC |
| ustekinumab (Stelara®, boDMARD) | No NOC | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| ustekinumab (Jamteki®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| ustekinumab (Steqeyma®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| ustekinumab (Wezlana®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
|
apremilast (Otezla®)
Auro-Apremilast, Jamp Apremilast, Sandoz Apremilast |
No NOC | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| baricitinib (Olumiant®) | Under Review | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
|
tofacitinib (Xeljanz®)
Auro-tofacitinib, Jamp tofacitinib, PMS-tofacitinib, Taro-tofacitinib |
Listed—CBC | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| upadacitinib (Rinvoq®) | Listed—CBC | No Info | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| 12th : Northwest Territories N/A | ||||||||
| generic name (Brand Name) | rheumatoid arthritis | axial spondyloarthritis | juvenile arthritis | psoriatic arthritis | lupus | vasculitis | osteoporosis | |
| ankylosing spondylitis | non-radiographic axial spondyloarthritis (not visible on X-ray) | |||||||
| abatacept (Orencia®) | Listed—CBC | No NOC | No NOC | Listed—CBC | Under Review | No NOC | No NOC | No NOC |
| adalimumab (Humira®, boDMARD) | Not Reimbursed | Not Reimbursed | No NOC | Not Reimbursed | Not Reimbursed | No NOC | No NOC | No NOC |
| adalimumab (Abrilada®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Amgevita®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Hadlima®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Hulio®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Hyrimoz®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Idacio®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Simlandi®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Yuflyma®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| anakinra (Kineret®) | Declined | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
| anifrolumab (Saphnelo®) | No NOC | No NOC | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC |
| belimumab (Benlysta®) | No NOC | No NOC | No NOC | No NOC | No NOC | Declined | No NOC | No NOC |
| bimekizumab (Bimzelx®) | No NOC | Under Review | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| canakinumab (Ilaris®) | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC | No NOC |
| certolizumab pegol (Cimzia®) | Listed—CBC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| denosumab (Prolia®, boDMARD) | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC |
| denosumab (Jubbonti®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | Under Review |
| etanercept (Enbrel®, boDMARD) | Not Reimbursed | Not Reimbursed | No NOC | Not Reimbursed | Not Reimbursed | No NOC | No NOC | No NOC |
| etanercept (Brenzys®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| etanercept (Erelzi®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| etanercept (Rymti®, bsDMARD) | No Info | No Info | No NOC | No Info | No Info | No NOC | No NOC | No NOC |
| golimumab (Simponi®) | Listed—CBC | Listed—CBC | Under Review | No Info | Listed—CBC | No NOC | No NOC | No NOC |
| guselkumab (Tremfya®) | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
| infliximab (Remicade®, boDMARD) | Not Reimbursed | Not Reimbursed | No NOC | No Info | Not Reimbursed | No NOC | No NOC | No NOC |
| infliximab (Avsola®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Inflectra®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Ixifi®, bsDMARD) | No Info | No Info | No NOC | No Info | No Info | No NOC | No NOC | No NOC |
| infliximab (Renflexis®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Remsima®, bsDMARD) | Declined | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
| ixekizumab (Taltz®) | No NOC | Under Review | No Info | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| rituximab (Rituxan®, boDMARD) | Not Reimbursed | No NOC | No NOC | No NOC | No NOC | No NOC | Not Reimbursed | No NOC |
| rituximab (Riabni®, bsDMARD) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC |
| rituximab (Riximyo®, bsDMARD) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC |
| rituximab (Ruxience®, bsDMARD) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC |
| rituximab (Truxima®, bsDMARD) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC |
| romosozumab (Evenity®) | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | Under Review |
| sarilumab (Kevzara®) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
| secukinumab (Cosentyx®) | No NOC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| tocilizumab (Actemra®) | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC |
| ustekinumab (Stelara®, boDMARD) | No NOC | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| ustekinumab (Jamteki®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | No Info | No NOC | No NOC | No NOC |
| ustekinumab (Steqeyma®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| ustekinumab (Wezlana®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | No Info | No NOC | No NOC | No NOC |
|
apremilast (Otezla®)
Auro-Apremilast, Jamp Apremilast, Sandoz Apremilast |
No NOC | No NOC | No NOC | No NOC | Declined | No NOC | No NOC | No NOC |
| baricitinib (Olumiant®) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
|
tofacitinib (Xeljanz®)
Auro-tofacitinib, Jamp tofacitinib, PMS-tofacitinib, Taro-tofacitinib |
Listed—CBC | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| upadacitinib (Rinvoq®) | Under Review | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| 13th : Yukon (Last year: 12th) | ||||||||
| generic name (Brand Name) | rheumatoid arthritis | axial spondyloarthritis | juvenile arthritis | psoriatic arthritis | lupus | vasculitis | osteoporosis | |
| ankylosing spondylitis | non-radiographic axial spondyloarthritis (not visible on X-ray) | |||||||
| abatacept (Orencia®) | Listed—CBC | No NOC | No NOC | Under Review | Under Review | No NOC | No NOC | No NOC |
| adalimumab (Humira®, boDMARD) | Not Reimbursed | Not Reimbursed | No NOC | Not Reimbursed | Not Reimbursed | No NOC | No NOC | No NOC |
| adalimumab (Abrilada®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Amgevita®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Hadlima®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Hulio®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Hyrimoz®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Idacio®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Simlandi®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Yuflyma®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| anakinra (Kineret®) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
| anifrolumab (Saphnelo®) | No NOC | No NOC | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC |
| belimumab (Benlysta®) | No NOC | No NOC | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC |
| bimekizumab (Bimzelx®) | No NOC | Under Review | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| canakinumab (Ilaris®) | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC | No NOC |
| certolizumab pegol (Cimzia®) | Listed—CBC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| denosumab (Prolia®, boDMARD) | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC |
| denosumab (Jubbonti®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | Under Review |
| etanercept (Enbrel®, boDMARD) | Not Reimbursed | Not Reimbursed | No NOC | Not Reimbursed | Not Reimbursed | No NOC | No NOC | No NOC |
| etanercept (Brenzys®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| etanercept (Erelzi®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| etanercept (Rymti®, bsDMARD) | No Info | No Info | No NOC | No Info | No Info | No NOC | No NOC | No NOC |
| golimumab (Simponi®) | Listed—CBC | Listed—CBC | Under Review | No Info | Listed—CBC | No NOC | No NOC | No NOC |
| guselkumab (Tremfya®) | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
| infliximab (Remicade®, boDMARD) | Listed—CBC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Avsola®, bsDMARD) | Under Review | Under Review | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| infliximab (Inflectra®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Ixifi®, bsDMARD) | No Info | No Info | No NOC | No Info | No Info | No NOC | No NOC | No NOC |
| infliximab (Renflexis®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Remsima®, bsDMARD) | Under Review | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
| ixekizumab (Taltz®) | No NOC | Under Review | No Info | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| rituximab (Rituxan®, boDMARD) | Not Reimbursed | No NOC | No NOC | No NOC | No NOC | No NOC | Not Reimbursed | No NOC |
| rituximab (Riabni®, bsDMARD) | Under Review | No NOC | No NOC | No NOC | No NOC | No NOC | Under Review | No NOC |
| rituximab (Riximyo®, bsDMARD) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC |
| rituximab (Ruxience®, bsDMARD) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC |
| rituximab (Truxima®, bsDMARD) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC |
| romosozumab (Evenity®) | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | Under Review |
| sarilumab (Kevzara®) | Under Review | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
| secukinumab (Cosentyx®) | No NOC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| tocilizumab (Actemra®) | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC |
| ustekinumab (Stelara®, boDMARD) | No NOC | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| ustekinumab (Jamteki®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | No Info | No NOC | No NOC | No NOC |
| ustekinumab (Steqeyma®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| ustekinumab (Wezlana®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | No Info | No NOC | No NOC | No NOC |
|
apremilast (Otezla®)
Auro-Apremilast, Jamp Apremilast, Sandoz Apremilast |
No NOC | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| baricitinib (Olumiant®) | Under Review | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
|
tofacitinib (Xeljanz®)
Auro-tofacitinib, Jamp tofacitinib, PMS-tofacitinib, Taro-tofacitinib |
Listed—CBC | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| upadacitinib (Rinvoq®) | Under Review | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
About the report card:
Arthritis Consumer Experts graded each of the provinces by assigning a score based upon number of medications listed, number under review, and number of declined listings. Because provincial formularies change frequently, we encourage you to contact the Ministry of Health in your province with questions you may have about medication listings of concern to you.
Definitions
| Declined: | The formulary does not reimburse patients prescribed this medication. The BC Drug Formulary uses the term “non-benefit”. |
| Listed—CBC: | Each province and territory has a process by which medications that are not normally included in the provincial, territorial or federal drug benefit lists are covered (or reimbursed). Approval of this drug is granted on a case-by-case basis. |
| Listed—ORC: | The medication is listed, but the criteria are not supported by medical evidence. Arthritis Consumer Experts considers these overly restrictive criteria (ORC) unacceptable. |
| No NOC: | No Notice of Compliance (or NOC) has been issued for this medication for this form of arthritis. |
| Under Review: | This drug has been approved by Health Canada for this disease type and the publicly funded drug plan is considering whether patients should be reimbursed for it. |
| No Info: | (No Information) The publicly funded drug plan has not provided information on status of medication reimbursement listing. |
| Delisted: | The formulary has delisted the originator biologic. |
* Note: The Non-Insured Health Benefits (NHIB) program provides supplementary health benefits, including prescription and non-prescription drugs, for registered First Nations and recognized Inuit throughout Canada.
Disclaimer: The material contained in this or any other ACE publication is provided for general information only. It should not be relied on to suggest a course of treatment for a particular individual or as a substitute for consultation with qualified health professionals who are familiar with your individual medical needs. If you have any healthcare related questions or concerns, you should contact your physician. Never disregard medical advice or delay in seeking it because of something you have read in any ACE publication.
Arthritis Consumer Experts
ACE thanks Arthritis Research Canada (ARC) for its scientific review of ACE and JointHealth™ information and education programs.